Humana (NYSE:HUM) Lowered to Hold Rating by StockNews.com

Humana (NYSE:HUM) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.

A number of other research analysts have also recently commented on the stock. Cantor Fitzgerald reissued a “neutral” rating and issued a $290.00 target price on shares of Humana in a report on Wednesday, February 12th. Royal Bank of Canada reiterated an “outperform” rating and set a $283.00 price objective on shares of Humana in a research report on Wednesday, February 12th. Barclays raised their target price on shares of Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a research report on Thursday, February 13th. Truist Financial upped their price target on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a report on Monday, January 6th. Finally, JPMorgan Chase & Co. dropped their price target on Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research note on Tuesday, February 18th. Nineteen equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $285.68.

Humana Price Performance

Shares of NYSE:HUM opened at $267.01 on Tuesday. The firm has a 50 day moving average of $271.43 and a 200-day moving average of $278.21. Humana has a 12 month low of $213.31 and a 12 month high of $406.46. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $32.23 billion, a PE ratio of 26.84, a PEG ratio of 2.05 and a beta of 0.57.

Humana (NYSE:HUM) last announced its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. On average, equities research analysts predict that Humana will post 16.47 EPS for the current fiscal year.

Insider Transactions at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.37% of the company’s stock.

Institutional Investors Weigh In On Humana

Institutional investors and hedge funds have recently made changes to their positions in the business. FPC Investment Advisory Inc. acquired a new position in Humana in the fourth quarter valued at approximately $27,000. Centricity Wealth Management LLC bought a new stake in shares of Humana in the 4th quarter valued at $30,000. LFA Lugano Financial Advisors SA lifted its position in shares of Humana by 56.3% during the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after acquiring an additional 45 shares during the period. OFI Invest Asset Management acquired a new position in shares of Humana during the 4th quarter valued at $33,000. Finally, Transce3nd LLC bought a new position in Humana during the fourth quarter worth $38,000. Institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.